Viridian Therapeutics has announced a major milestone in the treatment of thyroid eye disease (TED) after receiving approval from the U.S. Food and Drug Administration (FDA) for Lumvoa™ (veligrotug-vvze). The newly approved therapy represents an important advancement for patients living with TED, a rare autoimmune condition that can significantly affect vision, appearance, comfort, and quality of life.
Lumvoa is approved for the treatment of thyroid eye disease regardless of disease activity or duration, making it the first FDA-approved TED therapy with labeling that includes clinical data for both active and chronic forms of the condition.
According to Viridian Therapeutics, the approval is supported by results from two pivotal Phase 3 clinical studies, THRIVE and THRIVE-2. These trials evaluated Lumvoa in patients with active and chronic TED and demonstrated meaningful improvements in several key symptoms and signs associated with the disease.
Thyroid eye disease is an autoimmune disorder that causes inflammation and tissue changes around and behind the eyes. The condition is often associated with thyroid disorders, particularly Graves’ disease, and may result in symptoms such as bulging eyes, double vision, eye pain, redness, swelling, and vision difficulties.
TED can affect people physically and emotionally. Changes around the eyes can influence daily activities, confidence, and overall well-being. Many patients experience challenges with reading, driving, working, or performing routine tasks because of symptoms such as diplopia, also known as double vision.
Historically, treatment options for TED have been limited, especially for patients with chronic disease. The approval of Lumvoa provides a new therapeutic approach designed to address the underlying biology of TED.
The FDA approval of Lumvoa was supported by data from the THRIVE and THRIVE-2 Phase 3 clinical trials. These studies evaluated the effectiveness and safety of the therapy across different stages of thyroid eye disease.
Lumvoa is a full antagonist of insulin-like growth factor-1 receptor (IGF-1R), a target believed to play an important role in the development of TED. By blocking IGF-1R activity, Lumvoa is designed to reduce disease-related inflammation and tissue changes affecting the eyes.
In both clinical studies, Lumvoa achieved the primary endpoints and demonstrated statistically significant improvements in important TED outcomes. The treatment showed reductions in proptosis, commonly known as eye bulging, with improvements observed as early as three weeks in clinical studies.
The therapy also demonstrated benefits in diplopia response and complete resolution of double vision. Viridian stated that Lumvoa is the first approved TED treatment to show statistically significant effects in both diplopia response and complete resolution of diplopia in active and chronic TED.
Lumvoa is administered as a 12-week treatment course consisting of five intravenous infusions, with each infusion given every three weeks.
Viridian highlighted that the treatment program was designed with patient needs in mind, aiming to provide a defined treatment schedule while addressing important symptoms associated with TED.
Following FDA approval, Viridian announced plans for the immediate launch of Lumvoa in the United States. The company has also developed ViridianCares™, a patient support program intended to help eligible patients and caregivers navigate access, insurance support, and treatment assistance resources.
Like all medical treatments, Lumvoa includes important safety considerations. The FDA-approved safety information includes warnings and precautions related to several potential risks.
Reported adverse reactions may include infusion-related reactions, inflammatory bowel disease complications, increased blood glucose levels, and hearing impairment, including possible hearing loss.
Infusion reactions have been reported in some patients receiving Lumvoa. Symptoms may include temporary increases in blood pressure, fever, chills, headache, and fatigue. Healthcare providers may use preventive medications or adjust infusion rates when needed.
Patients receiving Lumvoa may also require monitoring for symptoms related to inflammatory bowel disease, blood sugar changes, and hearing issues. Physicians should evaluate the potential benefits and risks before and during treatment.
The most commonly reported adverse reactions include muscle spasms, headache, hearing impairment, hyperglycemia, fatigue, diarrhea, ear discomfort, nausea, infusion-related reactions, and hypertension.
The approval of Lumvoa represents a significant achievement for Viridian Therapeutics, as it becomes the company’s first FDA-approved medicine and first commercial product.
Based in Waltham, Massachusetts, Viridian focuses on developing medicines for autoimmune and rare diseases. The company is also advancing elegrobart, an investigational subcutaneous therapy for thyroid eye disease that is designed to improve treatment convenience.
Viridian has stated that elegrobart remains on track for a potential Biologics License Application (BLA) submission in 2027.
The company’s broader goal is to develop innovative antibody-based therapies that address unmet medical needs and improve outcomes for patients with serious autoimmune conditions.
The approval and launch of Lumvoa marks an important development in the evolving treatment landscape for thyroid eye disease. With clinical data supporting its use in both active and chronic TED, the therapy provides physicians with another option for managing a complex autoimmune condition.
For patients affected by TED, access to new treatments may offer hope for improved symptom control and better quality of life. As Lumvoa becomes available in clinical practice, ongoing monitoring and real-world experience will further shape understanding of its long-term role in TED management.
Viridian Therapeutics press release, “Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa™ (veligrotug-vvze) for the Treatment of Thyroid Eye Disease,” June 26, 2026.
This article is for informational and educational purposes only and does not constitute medical advice. Patients should consult qualified healthcare professionals for diagnosis, treatment decisions, and information about potential benefits and risks associated with any medication.
Most Accurate Healthcare AI designed for everything from admin workflows to clinical decision support.